Shots:
- AbbVie has reported topline P-III (UP-AA) trial data on Rinvoq (QD) for sev. alopecia areata in adults & adolescents with a mean baseline SALT score of 83.8
- Trial incl. 2 replicate studies (Study 1 & 2) in AA pts (n=1399; 12-64yrs.), where both studies’ Period A, pts were randomized to Rinvoq 15mg, 30mg, or PBO for 24wks. & in Period B, treatment continued or changed for 28wks. based on SALT score at wk. 24; pts could then enter Study 3 to receive Rinvoq for ~108wks.
- In Study 2, Rinvoq met the 1EP, with 44.6% & 54.3% vs 3.4% pts reaching ≥80% scalp hair coverage (SALT ≤20); 36% & 47.1% reached ≥90% coverage (SALT ≤10) vs 1.4%, with significant improvements also seen in eyebrows, eyelashes, & SALT=0 (2EPs) at 24wks.; Study 1 data to be reported by Q3’25
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie’s Rinvoq (Upadacitinib) Receives the US FDA’s Approval for Giant Cell Arteritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
